Status:
COMPLETED
The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Conditions:
Coronary Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the efficacy of 3 different drug-eluting-stent platforms to reduce coronary artery reblockage after stent implantation
Detailed Description
Coronary artery reblockage remains still a drawback of percutaneous coronary interventions even in the era of drug-eluting stents (DES). DESs working principle consists of the delivery of controlled a...
Eligibility Criteria
Inclusion
- Patients older than age 18 ´ presence of ischemic symptoms or evidence of myocardial ischemia in the presence of ≥50% de novo stenosis located in native coronary vessels written, informed consent by the patient or her/his legally-authorized representative for participation in the study.
Exclusion
- Target lesion located in the left main trunk or bypass graft In-stent restenosis Cardiogenic shock Malignancies or other comorbid conditions with life expectancy less than one year or that may result in protocol non-compliance Known allergy to the study medications: aspirin, clopidogrel, zotarolimus, sirolimus, stainless steel, or cobalt alloy Pregnancy (present, suspected or planned) or positive pregnancy test Previous enrollment in this trial Patient's inability to fully cooperate with the study protocol
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
1007 Patients enrolled
Trial Details
Trial ID
NCT00332397
Start Date
March 1 2006
End Date
July 1 2007
Last Update
June 17 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Deutsches Herzzentrum Muenchen
Munich, Germany, 80636
2
First Medizinische Klinik, Klinikum rechts der Isar
Munich, Germany, 81675